BiotechTube

ORIN1001

Phase 1/2Completed
0 watching 0 views this week⚡ Active
40
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Effect of Drug

Conditions

Effect of Drug

Trial Timeline

Jul 1, 2020 → Jan 30, 2025

NCT ID
NCT05154201

About ORIN1001

ORIN1001 is a phase 1/2 stage product being developed by Fosun Pharma for Effect of Drug. The current trial status is completed. This product is registered under clinical trial identifier NCT05154201. Target conditions include Effect of Drug.

Hype Score Breakdown

Clinical
13
Activity
8
Company
9
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT05154201Phase 1/2Completed

Competing Products

20 competing products in Effect of Drug

See all competitors
ProductCompanyStageHype Score
GP404141 + NplateGEROPHARMPhase 3
69
Milademetan Treatment A + Milademetan Treatment B + Milademetan Treatment CDaiichi SankyoPhase 1
33
E7386EisaiPhase 1
33
Duloxetine + WarfarinEli LillyPhase 1
33
Budesonide NasalJohnson & JohnsonApproved
85
SHR-1603Jiangsu Hengrui MedicinePhase 1
33
Famitinib + Ifosfamide + CamrelizumabJiangsu Hengrui MedicinePhase 1/2
41
Apatinib+IE + IEJiangsu Hengrui MedicinePhase 2
52
AZD7986, oral solution, 1 to 50 mg/mL + Placebo, oral solutionAstraZenecaPhase 1
33
AZD6482 + Clopidogrel + ASAAstraZenecaPhase 1
33
Albuterol Sulfate + Nicardipine Hydrochloride + Dobutamine Hydrochloride + Phenylephrine Hydrochloride + Verapamil Hydrochloride + Phentolamine Mesylate + PlaceboAstraZenecaPhase 1
33
esomeprazole/ASA Fixed Dose Combination (FDC)AstraZenecaPhase 1
33
AZD6482 + PlaceboAstraZenecaPhase 1
33
MSC2156119JMerckPhase 1
33
Docetaxel + PembrolizumabMerckPhase 2
52
daptomycinMerckPhase 3
77
Cyclosporine & Cellcept + Prograf & Cellcept + Low Dose CNI (Cyclosporine or FK) and Cellcept + Rapamune and CellceptRochePhase 1/2
41
EvolocumabAmgenPhase 1
32
GS-0976 + PlaceboGilead SciencesPhase 1
32
Varenicline (Champix)PfizerPhase 1
32